H elper T cells are classified into two subsets, T helper type 1 (Th1 ) and Th2 cells, based on the pattern of cytokine production. Th1 cells secrete Th1 cytokines such as interleukin -2 (IL -2 ) and interferon (IFN ) -and are responsible for cell -mediated immune responses, whereas Th2 cells secrete IL -4, IL -6, and IL -13 and have a potent helper function for antibody production. 1 The subsets are reciprocally inhibitory to the other subset through the cytokines they produce. Th1 cytokines can, therefore, produce antitumor effects, and forced expression of the Th1 -type cytokine genes in tumor cells elicits antitumor immunity. 2 Transfer of the Th1 cytokine genes has been examined for its clinical feasibility as a therapeutic strategy for cancer. 3 However, Th2 cytokines have been used to suppress excessive cell -mediated immunity such as autoimmune diseases. 4 IL-10 is a pleiotropic cytokine and is secreted from Th2 cells. 5 It stimulates B -cell differentiation and antibody production, but suppresses the secretion of inflammatory cytokines and IFN -from a number of cells including natural killer and Th1 cells. IL -10 also inhibits the functions of antigen -presenting cells. Consequently IL -10 downregulates cell -mediated immunity and increases host susceptibility to bacterial and parasitic infections. From a therapeutic point of view, transfer of the IL -10 gene is beneficial to ameliorate autoimmune arthritis 6 and to prolong allograft survival. 7 When cell -mediated immunity is influenced by the balance between Th1 and Th2 activity, IL -10 facilitates suppression of antitumor immunity. Previous studies showed that IL -10 inhibited the generation of cytotoxic T cells in vitro 8, 9 and that an elevated serum concentration of IL-10 was an unfavorable prognostic factor for patients with cancer. 10 -12 These data collectively imply that secretion of IL -10 from tumors plays an inhibitory role in antitumor responses and can promote the growth of IL -10 producing tumors. However, transfer of the IL-10 gene into tumors decreased their tumorigenicity and metastatic ability, and the mice that rejected IL -10 -producing tumors developed protective immunity. 13 -16 Activation of natural killer cells 14 and /or inhibition of angiogenesis through IFN - 16, 17 seem to contribute to the antitumor effects.
Our previous studies showed that transduction of murine colon carcinoma (Colon 26 ) cells with the Th1 but not Th2 cytokine ( IL -4 and IL -6 ) genes induced antitumor effects. 18 -20 We then examined again whether systemic immunity was influenced by the balance of Th1 and Th2 cytokines using IL -10 -secreting Colon 26 cells and found that the IL -10 producers suppressed systemic immune responses and growth of the tumors was augmented.
Materials and methods

Mice and cells
BALB / c or BALB /c nu/nu (6 -to 8 -week -old female ) were purchased from Japan SLC (Hamamatsu, Japan ). Colon 26, a carcinogen -induced undifferentiated colon adenocarcinoma cell line, was supplied by Dr. Hamuro ( Ajinomoto, Kawasaki, Japan ). Both ecotropic 2 and amphotropic PA317 packaging cells were obtained from the ATCC ( Manassas, VA ). These cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum.
Establishment of IL -10 -producing cells
Retrovirus vector LXSN 21 and mouse IL -10 cDNA were generously supplied by Dr. Miller (Fred Hutchinson Cancer Research Center, Seattle WA ) and Dr. Arai (Tokyo University, Tokyo, Japan ), respectively. The vector DNA harboring the IL -10 cDNA was transfected into ecotropic 2 cells using lipofectin reagent ( Life Technologies, Gaithersburg, MD ), and after the drug selection with G418 (Life Technologies ), cell -free supernatants of G418 -resistant clones were used as a stock. The culture supernatants containing retrovirus were incubated with amphotropic PA317 cells in the presence of 8 g/mL polybrene (Aldrich, Milwaukee, WI ) for infection. Among the G418 -resistant PA317 cells, a clone that expressed the highest level of IL -10 mRNA was selected and the culture supernatants were used for infecting Colon 18, 20 In vitro cell proliferation Cells ( 1Â10 5 ) were seeded in 6-cm dish in triplicate and counted on days 3, 5, and 7. 
Animal experiments
Transduced and /or wild -type Colon 26 cells ( 1Â10 6 ) were injected subcutaneously into the flank of mice. The mice that had rejected Colon 26/ IL-2 or Colon 26/IL -12 cells were inoculated with wild -type or IL -10 producer cells on day 25 in a rechallenge experiment. Tumor volumes were calculated according to the following formula: 1 /2ÂlengthÂ(width ). 2 Statistical analysis was performed by one -way analysis of variance ( ANOVA ) or Fisher's exact probability test. All of the animal studies were performed in accordance with the laboratory animal resources guidelines of Chiba Cancer Center Research Institute. The proliferation rate in vitro of Colon 26 /IL -10H cells was the same as that of wild -type ( Fig 1B ) and Colon 26 / -gal ( data not shown) cells, and the expression level of class I antigens of major histocompatibility complex (H -2K and H -2D ) on Colon 26/ IL-10H cells were not markedly different from that of wild -type cells (Fig 1C ) . Enzymelinked immunosorbent assays showed that serum IL -10 concentrations of any of the mice bearing wild -type and/ or Colon 26 /IL -10H tumors were less than 1 pg/ mL irrespective of the tumor size.
Suppressed antitumor immunity by Colon 26 / IL -10 tumors
We inoculated syngeneic nude mice with wild -type or Colon 26 /IL -10H cells to examine whether mature T cells were required for the accelerated growth of Colon 26 /IL -10H tumors (Fig 2 ) . The growth of Colon 26 /IL -10H tumors was significantly augmented compared with that of wildtype tumors in nude (P < .01, days 19, 22 and 25) as well as in immunocompetent mice ( P <.01, days 18, 22 and 25 ), Standard error bars are also shown.
Cancer Gene Therapy IL-10-suppressed antitumor immunity Kawamura et al suggesting that non -T cells are involved in the enhanced tumor growth. We then examined the growth of wild -type and Colon 26 /IL -10H tumors in immunocompetent and nude mice that were inoculated with respective cells in the different flank of the same mice (Fig 3 ) . The growth of wild -type tumors in BALB /c mice bearing both wild -type and Colon 26/IL -10H tumors was significantly greater than that of wild -type tumors developed in the mice bearing wild -type tumors in both flanks (P < .01, days 12, 15, and 19 ). The growth augmentation reached a level similar to that of Colon 26/IL -10H tumors developed in the mice bearing both wild -type and Colon 26 /IL -10H tumors or Colon 26 /IL -10H tumors alone ( Fig 3A ) . These data suggest that Colon 26/ IL-10H tumors suppressed systemic antitumor immunity and allowed accelerated growth of wild -type tumors. In contrast, wild -type tumors marginally affected the growth of wild -type or Colon 26 /IL -10H tumors developed at different site.
We performed the same experiment in nude mice ( Fig 3B ) . The growth of wild -type tumors was not influenced by wild -type or Colon 26 /IL -10H tumors developed in the same mice. Under the T cell -defective condition suppression of systemic immunity by Colon 26/ IL -10H tumors was not observed.
Impaired protective immunity by Colon 26 / IL -10 tumors
Our previous reports demonstrated that BALB /c mice rejected Colon 26 /IL -2 and Colon 26/ IL-12 cells and that the mice became resistant to wild -type Colon 26 but not other syngeneic tumor cells challenged subsequently 18, 20 ( Table 1) 
Expression of IL -10 -related genes in wild -type and Colon 26 / IL -10 tumors
Because several kinds of protein played an crucial role in IL -10-mediated antitumor effects, 16, 17, 22 we examined the expression of these genes in wild -type or Colon 26/ IL-10H cells and their tumors (10 specimens ) using RT-PCR ( Fig 4) . The expression level of the IFN -and Mig -1 genes was not different between wild -type and Colon 26 /IL -10H tumors. The level in both types of tumors was significantly higher than that of respective cultured cells, suggesting that tumor-infiltrating cells but not tumors themselves expressed the genes. The expression level of the VEGF gene was slightly lower in some wild -type tumors than in Colon 26 / IL -10H tumors but the level in tumors was not markedly different from respective tumor cells cultured in vitro. The expression level of the iNOS gene was not different between wild -type and Colon 26 /IL -10H tumors but the level of cultured Colon 26 /IL -10H cells was significantly lower than that of cultured wild -type cells.
Discussion
In this study we demonstrated that secretion of IL -10 from tumors suppressed T cell -mediated systemic immunity. Accelerated growth of wild -type Colon 26 tumors in the mice bearing Colon 26 /IL -10H tumors on the other flank was due to inhibition of mature T cell -mediated antitumor effects, because the same growth augmentation zA number of tumor -bearing mice / the total number of mice inoculated.
xColon 26 / IL -10H cells developed tumors. was not observed in nude mice. Moreover, inoculation of Colon 26/ IL -10H tumors could induce an anergy state in the mice that developed protective immunity. IL-10 is known to inhibit the function of antigen -presenting cells and generation of cytotoxic T cells 5, 8 and we suggested in the present study that IL -10 could also suppress the activity and/ or migration of cytotoxic T cells, which were already induced. Concentrations of serum IL-10 in the mice bearing Colon 26 /IL -10H tumors were lower than the amount of IL -10 secreted from IL -10 low-producers whose growth in vivo was not significantly different from that of wild -type tumors. The augmented growth of wild -type tumors developed on the other side of Colon 26 /IL -10H tumors was thereby not due to a direct action of IL -10 released from Colon 26/IL -10H tumors but probably due to tolerated cytotoxic T cells. The effector cells, which were responsible for accelerated tumor growth was not exclusively T cells, because the enhanced growth of Colon 26/IL -10H tumors was also observed in nude mice and severe combined immunodeficient mice (data not shown ). IL-10 -mediated suppression of antitumor immunity observed in the present study was therefore attributable to both T and non -T cells acting systemically and locally. However, histological examination of wild -type and Colon 26/ IL-10H tumors in both immunocompetent and immunocompromized mice did not reveal any significant difference in cell populations that migrated into the tumors ( data not shown ).
Adris et al 23 recently reported that Colon 26 cells transduced with the IL -10 gene did not develop tumors in the inoculated mice due to T cell-dependent immune responses. Although the expression of the class I antigens on their transduced cells was up -regulated compared with that of their untransduced cells, the discrepant results between our and their study could be in part due to the amount of IL-10 secreted: Their transduced cells secreted IL -10 about 100 times more than our Colon 26/ IL -10H cells did. A high dose of IL-10 might mask its suppressive effects and in turn activate T cells. 24 In transgenic mice expressing IL -10 under the control of the IL -2 promoter, the growth of lung tumors inoculated in the mice was enhanced due to the inhibition of antigen-presenting cells. 25 Because the production level of IL -10 in the transgenic mice was similar to that of Colon 26 /IL -10H cells in the present study, physiological levels of IL-10 are inhibitory to systemic immunity. However, antitumor activities were also evidenced with tumor cells producing a similar amount of IL -10 as Colon 26/ IL-10H cells, 26 suggesting that a repertoire of IL -10 -responsive immunocompetent cells but not the amount of produced IL -10 was correlated with the effect on tumor growth.
Previous studies showed that IL -10 -mediated antitumor effects were ascribed to stimulation and /or chemotaxis of immunocompetent cells 13, 15, 23 and to antiangiogenic properties that were in part due to decreased VEGF expression. 16 IFN -has both immune stimulatory and antiangiogenic activities, and is induced by IL -10 gene expression 17 Kundu et al 22 also reported that IL -10 up-regulated the expression of iNOS gene and induced iNOS in IL -10 -expressing tumors produced antitumor effects. The present study, however, showed that expression of the IFN -, IFN --induced Mig -1, VEGF, and iNOS genes were not different between wild -type and Colon 26/ IL-10H tumors and that most of the IFN -and Mig -1 transcripts detected in these tumors were derived from the cells infiltrated into these tumors. Although RT-PCR is not a quantitative assay, these data suggested that none of the genes examined would play a crucial role( s) in the IL-10 -mediated responses in the present study. Expression of the iNOS gene in cultured Colon 26 /IL -10H cells was down -regulated but the reason remained uncharacterized.
Our present data showed that suppressed cell -mediated immunity was generated under IL -10 -induced Th2 dominant states. Because clinical studies suggested that production of IL -10 from tumors or elevated serum IL -10 concentrations could be a poor prognostic factor, 10 -12 this experimental model is a good animal model to study the immune-tolerant state of patients with cancer. Forced expression of the IL -10 gene thereby cannot be always a therapeutic strategy for cancer. In contrast, inhibition of Th2 -mediated immune responses such as dominant negative form of IL -10 would be an approach for cancer treatment.
